Protalix Biotherapeutics Inc
F:PBDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Protalix Biotherapeutics Inc
F:PBDA
|
US |
|
H
|
Hanover Insurance Group Inc
XBER:AF4
|
US |
|
Mauna Kea Technologies SA
F:1MK
|
FR |
|
DSM-Firmenich AG
F:ZX6
|
CH |
|
I
|
Impala Platinum Holdings Ltd
XMUN:IPHB
|
ZA |
|
V
|
Vishay Intertechnology Inc
DUS:VHY
|
US |
|
D
|
Ducommun Inc
F:DUM
|
US |
|
S
|
Shanghai Electric Group Co Ltd
XMUN:USR
|
CN |
|
Huaneng Power International Inc
SSE:600011
|
CN |
|
F
|
Forvia SE
XMUN:FAU
|
FR |
Wall St Price Targets
PBDA Price Targets Summary
Protalix Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for PBDA is 9.358 EUR with a low forecast of 8.424 EUR and a high forecast of 10.509 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PBDA's stock price target?
Price Target
9.358
EUR
According to Wall Street analysts, the average 1-year price target for PBDA is 9.358 EUR with a low forecast of 8.424 EUR and a high forecast of 10.509 EUR.
What is the Revenue forecast for Protalix Biotherapeutics Inc?
Projected CAGR
9%
Over the last 14 years, the compound annual growth rate for Revenue has been 23%. The projected CAGR for the next 3 years is 9%.
What is the Gross Profit forecast for Protalix Biotherapeutics Inc?
Projected CAGR
7%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 23%. The projected CAGR for the next 6 years is 7%.
